114 related articles for article (PubMed ID: 21956605)
1. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment.
Hariharan S; Madabushi R
J Clin Pharmacol; 2012 Jan; 52(1 Suppl):119S-25S. PubMed ID: 21956605
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation.
Mack DR; Kim JJ
Ann Pharmacother; 2012; 46(7-8):1105-10. PubMed ID: 22764329
[TBL] [Abstract][Full Text] [Related]
3. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease.
Khadzhynov D; Wagner F; Formella S; Wiegert E; Moschetti V; Slowinski T; Neumayer HH; Liesenfeld KH; Lehr T; Härtter S; Friedman J; Peters H; Clemens A
Thromb Haemost; 2013 Apr; 109(4):596-605. PubMed ID: 23389759
[TBL] [Abstract][Full Text] [Related]
4. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
Clemens A; Haertter S; Friedman J; Brueckmann M; Stangier J; van Ryn J; Lehr T
Curr Med Res Opin; 2012 Feb; 28(2):195-201. PubMed ID: 22208675
[TBL] [Abstract][Full Text] [Related]
5. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.
Lehr T; Haertter S; Liesenfeld KH; Staab A; Clemens A; Reilly PA; Friedman J
J Clin Pharmacol; 2012 Sep; 52(9):1373-8. PubMed ID: 21956604
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.
Bouchard J; Ghannoum M; Bernier-Jean A; Williamson D; Kershaw G; Weatherburn C; Eris JM; Tran H; Patel JP; Roberts DM
Clin Toxicol (Phila); 2015 Mar; 53(3):156-63. PubMed ID: 25661675
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.
Wychowski MK; Kouides PA
Ann Pharmacother; 2012 Apr; 46(4):e10. PubMed ID: 22496474
[TBL] [Abstract][Full Text] [Related]
9. Pharmacometric characterization of dabigatran hemodialysis.
Liesenfeld KH; Staab A; Härtter S; Formella S; Clemens A; Lehr T
Clin Pharmacokinet; 2013 Jun; 52(6):453-62. PubMed ID: 23529813
[TBL] [Abstract][Full Text] [Related]
10. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
van Ryn J; Grottke O; Spronk H
Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran overdose secondary to acute kidney injury and amiodarone use.
Fountzilas C; George J; Levine R
N Z Med J; 2013 Mar; 126(1370):110-2. PubMed ID: 23474519
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin.
Stangier J; Stähle H; Rathgen K; Roth W; Reseski K; Körnicke T
J Clin Pharmacol; 2012 Feb; 52(2):243-50. PubMed ID: 21868715
[TBL] [Abstract][Full Text] [Related]
13. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
14. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran monitoring made simple?
Eikelboom JW; Weitz JI
Thromb Haemost; 2013 Sep; 110(3):393-5. PubMed ID: 23884303
[No Abstract] [Full Text] [Related]
17. Dabigatran: how the drug company withheld important analyses.
Cohen D
BMJ; 2014 Jul; 349():g4670. PubMed ID: 25055829
[No Abstract] [Full Text] [Related]
18. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
Bendel SD; Bona R; Baker WL
Adv Ther; 2011 Jun; 28(6):460-72. PubMed ID: 21533567
[TBL] [Abstract][Full Text] [Related]
19. [Re-allign (randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran ftexilate in patients after heart valve replacement)].
Zeus T; Nitschmann S; Kelm M
Internist (Berl); 2014 Sep; 55(9):1108-9, 1111. PubMed ID: 25070615
[No Abstract] [Full Text] [Related]
20. Concerns over data in key dabigatran trial.
Cohen D
BMJ; 2014 Jul; 349():g4747. PubMed ID: 25055831
[No Abstract] [Full Text] [Related]
[Next] [New Search]
